Verrica Pharmaceuticals Inc. Interest Expense
Verrica Pharmaceuticals Inc. (VRCA) reported Interest Expense of $2.37 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-08-14
- Verrica Pharmaceuticals Inc. interest expense for the quarter ending 2024-06-30 was $2.37M.
- Verrica Pharmaceuticals Inc. interest expense for the quarter ending 2024-03-31 was $2.32M.
- Verrica Pharmaceuticals Inc. interest expense for the quarter ending 2023-12-31 was $2.31M.
- Verrica Pharmaceuticals Inc. interest expense for the quarter ending 2023-09-30 was $1.66M, a 1945.68% increase year-over-year.
- Verrica Pharmaceuticals Inc. interest expense for fiscal 2023 was $3.96M, a 82.41% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. interest expense for fiscal 2022 was $2.17M, a 49.43% decline from fiscal 2021.
- Verrica Pharmaceuticals Inc. interest expense for fiscal 2021 was $4.29M, a 41.56% increase from fiscal 2020.
- Verrica Pharmaceuticals Inc. interest expense for fiscal 2020 was $3.03M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $2.37M 10-Q · filed 2024-08-14 | $4.69M 10-Q · filed 2024-08-14 | $6.99M derived: sum of 3 quarters · filed 2024-08-14 | $8.65M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2024-03-31 | $2.32M 10-Q · filed 2024-05-13 | $4.62M derived: sum of 2 quarters · filed 2024-05-13 | $6.28M derived: sum of 3 quarters · filed 2024-05-13 | $6.28M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.96M derived: sum of 2 quarters · filed 2024-02-29 | $3.96M derived: sum of 3 quarters · filed 2024-08-14 | $3.96M 10-K · filed 2024-02-29 | |
| 2023-09-30 | $1.66M 10-Q · filed 2023-11-09 | $1.66M derived: sum of 2 quarters · filed 2024-08-14 | $1.66M 10-Q · filed 2023-11-09 | $1.66M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-08-14 | $81.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | $81.00K derived: sum of 3 quarters · filed 2024-05-13 | $1.15M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $81.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.15M derived: sum of 3 quarters · filed 2024-02-29 | $2.17M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $81.00K 10-Q · filed 2023-11-09 | $1.15M derived: sum of 2 quarters · filed 2023-11-09 | $2.17M 10-Q · filed 2023-11-09 | $3.33M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.07M 10-Q · filed 2023-08-08 | $2.09M 10-Q · filed 2023-08-08 | $3.25M derived: sum of 3 quarters · filed 2023-08-08 | $4.34M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $1.08M 10-Q · filed 2023-05-09 | $2.18M derived: sum of 2 quarters · filed 2023-05-09 | $3.27M derived: sum of 3 quarters · filed 2023-05-09 | $4.35M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.19M derived: sum of 2 quarters · filed 2023-03-06 | $3.27M derived: sum of 3 quarters · filed 2023-03-06 | $4.29M 10-K · filed 2023-03-06 | |
| 2021-09-30 | $1.09M 10-Q · filed 2022-11-07 | $2.17M derived: sum of 2 quarters · filed 2022-11-07 | $3.20M 10-Q · filed 2022-11-07 | $4.19M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | $1.08M 10-Q · filed 2022-08-11 | $2.11M 10-Q · filed 2022-08-11 | $3.10M derived: sum of 3 quarters · filed 2022-08-11 | $4.01M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $1.03M 10-Q · filed 2022-05-09 | $2.02M derived: sum of 2 quarters · filed 2022-05-09 | $2.94M derived: sum of 3 quarters · filed 2022-05-09 | $3.84M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $1.91M derived: sum of 2 quarters · filed 2022-03-02 | $2.81M derived: sum of 3 quarters · filed 2022-03-02 | $3.03M 10-K · filed 2022-03-02 | $3.03M 10-K · filed 2021-03-17 |
| 2020-09-30 | $918.00K 10-Q · filed 2021-11-12 | $1.82M derived: sum of 2 quarters · filed 2021-11-12 | $2.04M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $904.00K 10-Q · filed 2021-08-10 | $1.12M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | $220.00K 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |